What's the Buzz About Hydroxynorketamine? Is It the History, the Story, the Debate, or the Promise?

Biological Psychiatry

Volumn 81, Issue 8, 2017, Pages e61-e63

  Abdallah, Chadi G ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ESKETAMINE; GLUTAMIC ACID; HYDROXYNORKETAMINE; KETAMINE; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; ENANTIOMER; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL SLICE; HUMAN; MAJOR DEPRESSION; NEUROTRANSMISSION; NONHUMAN; NOTE; PRIORITY JOURNAL; SYNAPTOGENESIS;

EID: 85015287436     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2017.01.002     Document Type: Note

References (10)

1. 1 Skolnick, P., Layer, R.T., Popik, P., Nowak, G., Paul, I.A., Trullas, R., Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry 29 (1996), 23–26.
2. 2 Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
3. 3 Maeng, S., Zarate, C.A. Jr., Du, J., Schloesser, R.J., McCammon, J., Chen, G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63 (2008), 349–352.
4. 4 Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
5. 5 Abdallah, C.G., Adams, T.G., Kelmendi, B., Esterlis, I., Sanacora, G., Krystal, J.H., Ketamine׳s mechanism of action: A path to rapid-acting antidepressants. Depress Anxiety 33 (2016), 689–697.
6. 6 Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
7. 7 Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.
8. 8 Zarate, C.A. Jr., Brutsche, N., Laje, G., Luckenbaugh, D.A., Venkata, S.L., Ramamoorthy, A., et al. Relationship of ketamine׳s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72 (2012), 331–338.
9. 9 Collingridge, G.L., Lee, Y., Bortolotto, Z.A., Kang, H., Lodge, D., Antidepressant actions of ketamine versus hydroxynorketamine. Biol Psychiatry 81 (2017), e65–e67.
10. 10 Zanos, P., Moaddel, R., Morris, P.J., Wainer, I.W., Albuquerque, E.X., Thompson, S.M., et al. Reply to: Antidepressant actions of ketamine versus hydroxynorketamine. Biol Psychiatry 81 (2017), e69–e71.